Tirzepatide Cut Type 2 Diabetes Risk by 93% Over 3 Years While Producing Up to 20% Weight Loss

Three years of once-weekly tirzepatide in people with obesity and prediabetes produced sustained weight loss of 12-20% (dose-dependent) versus 1.3% with placebo. Most remarkably, tirzepatide reduced progression to type 2 diabetes by 93% (1.3% vs 13.3%, HR 0.07, p<0.001). Even after 17 weeks off treatment, diabetes protection persisted (2.4% vs 13.7%, HR 0.12). The most common side effects were GI symptoms, mostly mild-moderate during dose escalation, with no new safety signals over 3 years.

Phase 3, double-blind, randomized, placebo-controlled trial (SURMOUNT-1). 2,539 total participants randomized 1:1:1:1 to tirzepatide 5mg, 10mg, or 15mg weekly or placebo. This analysis focused on the 1,032 participants with obesity and prediabetes, treated for 176 weeks (3.4 years) followed by a 17-week off-treatment period. Key endpoints: percent weight change at 176 weeks and type 2 diabetes onset during treatment and off-treatment periods.

This is the first major trial to demonstrate that a peptide drug can prevent type 2 diabetes while simultaneously treating obesity over 3 years. A 93% reduction in diabetes onset is among the largest preventive effects ever demonstrated for any medication, potentially reframing obesity treatment as diabetes prevention.

This study marks a paradigm shift in how we think about obesity and diabetes. Tirzepatide is the first peptide drug to demonstrate both substantial long-term weight loss and near-complete prevention of diabetes progression in a single treatment. Combined with the success of semaglutide in the STEP and SELECT trials, these results cement incretin-based peptide therapies as potentially the most transformative class of drugs in a generation — treating obesity as a disease rather than a lifestyle issue and preventing its most devastating consequences.

Industry-funded (Eli Lilly). The analysis focused on the prediabetes subgroup (1,032 of 2,539 total participants). Weight regain and diabetes onset after long-term drug discontinuation beyond 17 weeks remain unknown. Cost and access barriers may limit real-world impact. GI side effects during dose escalation may affect tolerability.